Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
The research, taken from the CLARITY study and published in GUT, found that 865 people given the Pfizer/BioNTech or the Oxford/AZ COVID-19 vaccine and treated with infliximab (Remicade) had significantly lower concentrations of antibodies when compared to 428 people on an alternative treatment, vedolizumab (Entyvio). Infliximab is prescribed to around two million people worldwide.
Allergy & Immunology May 5th 2021
Blood
This Research Article from Blood – available as a PDF – discusses two main points. First, antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. The second point shows that, in patients treated with either Bruton’s tyrosine kinase inhibitors (TKIs) or venetoclax ± anti-CD20 antibody, responses are relatively low.
Hematology April 27th 2021
Based on the Medicus Firm’s hundreds of job searches and placements across the US, the results are a case of good news and bad news. The bad? Elective procedures canceled, hiring slowed, and signing bonuses stalled. However, the good news is that those people canceling the elective procedures still need them, bringing about a necessary return to a high-demand healthcare environment.
Allergy & Immunology April 27th 2021
This article from the American College of Physicians (ACP) provides a deeper dive into the pause of the J&J vaccine, which was recommended by the FDA and CDC on April 13, 2021, after six cases of cerebral venous sinus thrombosis (CVST) among patients who had received the vaccine was reported. The pause is being done to determine whether the vaccine is associated with any other types of thrombosis and to develop more specific recommendations for its use, possibly based on age.
Cardiology April 27th 2021
The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech vaccine.
Hematology March 30th 2021
In this podcast/article from KevinMD, the story of Dr. Hasan Gokal is examined, a Houston physician who was fired from his public health job and was subsequently faced with criminal charges for stealing a vial of the vaccine. His case was also brought to the Texas Medical Board. In a sea of regulations and protocols, were his actions well-intentioned and in the best interest of patient care and safety?
Allergy & Immunology March 30th 2021